Kevin M Maloney1, Adrien Le Guillou1,2, Robert A Driggers1, Supriya Sarkar1,3, Emeli J Anderson1, Amyn A Malik1,4,5, Samuel M Jenness1. 1. Department of Epidemiology, Emory University, Atlanta, Georgia, USA. 2. Department of Research and Public Health, Reims Teaching Hospitals, Robert Debré Hospital, Reims, France. 3. ViiV Healthcare, Research Triangle, North Carolina, USA. 4. Yale Institute for Global Health, New Haven, Connecticut, USA. 5. Yale School of Medicine, New Haven, Connecticut, USA.
Abstract
BACKGROUND: Long-acting injectable (LAI) human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) is reportedly efficacious, although full trial results have not been published. We used a dynamic network model of HIV transmission among men who have sex with men to assess the population impact of LAI-PrEP when available concurrently with daily-oral (DO) PrEP. METHODS: The reference model represents the current HIV epidemiology and DO-PrEP coverage (15% among those with behavioral indications for PrEP) among men who have sex with men in the southeastern United States. Primary analyses investigated varied PrEP uptake and proportion selecting LAI-PrEP. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and LAI-PrEP persistence relative to DO-PrEP. RESULTS: Compared with the reference scenario, if 50% chose LAI-PrEP, 4.3% (95% simulation interval, -7.3% to 14.5%) of infections would be averted over 10 years. The impact of LAI-PrEP is slightly greater than that of the DO-PrEP-only regimen, based on assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% (95% simulation interval, 6.7%-26.4%) of infections would be averted. The highest population-level impact occurred when LAI-PrEP uptake and persistence improved. CONCLUSIONS: If LAI-PrEP replaces DO-PrEP, its availability will modestly improve the population impact. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage, or if persistence is greater for LAI-PrEP.
BACKGROUND: Long-acting injectable (LAI) human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) is reportedly efficacious, although full trial results have not been published. We used a dynamic network model of HIV transmission among men who have sex with men to assess the population impact of LAI-PrEP when available concurrently with daily-oral (DO) PrEP. METHODS: The reference model represents the current HIV epidemiology and DO-PrEP coverage (15% among those with behavioral indications for PrEP) among men who have sex with men in the southeastern United States. Primary analyses investigated varied PrEP uptake and proportion selecting LAI-PrEP. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and LAI-PrEP persistence relative to DO-PrEP. RESULTS: Compared with the reference scenario, if 50% chose LAI-PrEP, 4.3% (95% simulation interval, -7.3% to 14.5%) of infections would be averted over 10 years. The impact of LAI-PrEP is slightly greater than that of the DO-PrEP-only regimen, based on assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% (95% simulation interval, 6.7%-26.4%) of infections would be averted. The highest population-level impact occurred when LAI-PrEP uptake and persistence improved. CONCLUSIONS: If LAI-PrEP replaces DO-PrEP, its availability will modestly improve the population impact. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage, or if persistence is greater for LAI-PrEP.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Jeffrey T Parsons; H Jonathon Rendina; Jonathan M Lassiter; Thomas H F Whitfield; Tyrel J Starks; Christian Grov Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy Journal: N Engl J Med Date: 2015-12-01 Impact factor: 91.245
Authors: Katie B Biello; Sybil Hosek; Morgan T Drucker; Marvin Belzer; Matthew J Mimiaga; Elliot Marrow; Julia Coffey-Esquivel; Jennifer Brothers; Kenneth H Mayer Journal: Arch Sex Behav Date: 2017-09-19
Authors: Julia L Marcus; Leo B Hurley; Dong Phuong Nguyen; Michael J Silverberg; Jonathan E Volk Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Douglas Krakower; Kevin M Maloney; Victoria E Powell; Ken Levine; Chris Grasso; Kathy Melbourne; Julia L Marcus; Kenneth H Mayer Journal: J Int AIDS Soc Date: 2019-02 Impact factor: 5.396
Authors: Norma S Harris; Anna Satcher Johnson; Ya-Lin A Huang; Dayle Kern; Paul Fulton; Dawn K Smith; Linda A Valleroy; H Irene Hall Journal: MMWR Morb Mortal Wkly Rep Date: 2019-12-06 Impact factor: 17.586
Authors: Deven T Hamilton; Clara Agutu; Joseph B Babigumira; Elise van der Elst; Amin Hassan; Evanson Gichuru; Peter Mugo; Carey Farquhar; Thumbi Ndung'u; Martin Sirengo; Wairimu Chege; Steven M Goodreau; Adam Elder; Eduard J Sanders; Susan M Graham Journal: J Acquir Immune Defic Syndr Date: 2022-05-05 Impact factor: 3.771
Authors: Matthew E Levy; Anya Agopian; Manya Magnus; Anthony Rawls; Jenevieve Opoku; Michael Kharfen; Alan E Greenberg; Irene Kuo Journal: J Acquir Immune Defic Syndr Date: 2021-03-01 Impact factor: 3.771
Authors: Adrien Le Guillou; Susan Buchbinder; Hyman Scott; Albert Liu; Diane Havlir; Susan Scheer; Samuel M Jenness Journal: J Acquir Immune Defic Syndr Date: 2021-12-01 Impact factor: 3.771